Introduction
Up to 50% of the metastatic breast cancer (mBC) patients eventually develop liver metastases which is associated with a poor overall survival ranging from 1-3 years. 1, 2 Liver metastatic breast cancer (LMBC) patients with limited (extra) hepatic disease can obtain a survival benefit from local treatment options, such as surgery and ablation. 3, 4 Unfortunately, most LMBC patients have extended disease whereby systemic treatment by chemotherapy or anti-hormonal therapy, in hormone sensitive breast cancer, is indicated. Systemic treatment with chemotherapy has lengthened overall survival, but haematological, gastrointestinal and neurotoxicity are dose-limiting factors with systemic administration of these agents. 5 Therapies with less systemic toxicity are therefore an attractive treatment option in LMBC patients refractory to systemic chemotherapy. 6 Several intra-arterial therapies have been applied for LMBC patients, such as radioembolization (Yttrium-90 ( 90 Y) resin microspheres), chemo embolization and chemo infusion, reported as effective and safe treatment options. [7] [8] [9] Of these treatments, the best results are reported for intraarterial radioembolization, with a disease control rate of 72-91% and an overall survival of 6.6-13.6 months. 7, [10] [11] [12] For over 15 years, LMBC patients are treated by intra-arterial chemo infusion with mitomycin C (MMC) in our institute whereby disease control is obtained in 58% with low adverse events in a very heavily pre-treated cohort. 9 Since primary breast cancer is sensitive for both systemic chemotherapy and external beam radiation therapy, LMBC patients might also benefit from the combined treatment of chemo infusion and selective internal radiation therapy (SIRT).
However, the sequential administration of these intra-arterial therapies e.g. SIRT and intra-arterial chemo infusion, has not yet been reported. In this pilot study we prospectively analysed the safety and feasibility of the sequential intra-arterial infusion of 90 Y resin microspheres and MMC in patients refractory to conventional systemic chemotherapy.
Patients and methods
This prospective phase I pilot study of 16 patients was approved by the ethics committee of our hospital (S 53657). Patients were included from April 2012 until March 2018. All patients signed a written informed consent. Patient selection was performed by a multidisciplinary tumour board consisting of medical, surgical and radiation oncologists together with pathologists, nuclear medicine physicians and (interventional) radiologists.
In Table 1 , the inclusion and exclusion criteria for this pilot study are shown. Figure 1 shows the treatment schedule of 90 Y SIRT followed by MMC infusion in the different cohorts. The first 3 patients were allocated to cohort A, the second 3 patients to cohort B, the 3 patients thereafter to cohort C and the remaining of the patients in cohort D. Patients first underwent the 90 Y treatment and in the absence of progression, the sequential intra-arterial hepatic MMC infusions were administrated 8 weeks later.
Radioembolization with Yttrium-90 ( 90 Y) resin microspheres
All 90 Y procedures were performed under local anaesthesia by or under direct supervision of an expert interventional radiologist (GM) and nuclear medicine physician (CD). Previously published work describes the details of the 90 Y treatment. 13 Briefly, patients first underwent a detailed baseline angiogram and embolization of enterohepatic arteries with micro-coils according to the expertise of the interventional radiologist. Technetium-99mmacroaggregated albumin ( 99m TC-MAA) was injected in the target vessels and a planar scintigraphy was performed to determine the lung shunt fraction. Two weeks later patients underwent bi-lobar or uni-lobar injection of 90 Y resin microspheres (SIR spheres , Sirtex Inc, Cosgrove, Australia) under local anaesthesia. The activity of 90 Y injected in the patient was calculated based on the body surface area method. In patients where it was possible to use the partition model, the partition model was used instead of the body surface area method. Dependent on the site of lesions, the 90 Y resin microspheres were injected intra-arterially via a micro catheter to the right and left liver lobe (superselective). A Progreat® micro catheter (Terumo, Europe) or an anti-reflux catheter (Surefire Inc., Westminster, CO, USA) was used for injection of the microspheres.
Patients received antiemetics and morphine derivates before 90 Y injection when required.
Hepatic intra-arterial chemo infusion with MMC
Six to eight weeks after the 90 Y treatment, patients underwent response assessment by magnetic resonance imaging (MRI) of the liver and a whole body [ 18 F]-FDG positron emission tomography/ computed tomography scan ( 18 F-FDG PET/CT) together with laboratory tests. If patients showed no untreatable progression of disease on MRI and 18 F-FDG PET-CT scan (bases on RECIST criteria 1.1) together with acceptable laboratory results (> 100x10 9 thrombocytes/L), the intra-arterial chemoinfusion of MMC could be administrated. Six to ten weeks after the 90 Y procedure, patients received the first infusion of MMC, as previously described by our group. 14 After local anaesthesia, vascular access was obtained by the right common femoral artery and, using a diagnostic 4-French catheter, a micro catheter was placed in the right and left hepatic arteries for injection of MMC in both liver lobes.
Ascending maximal doses of MMC were administrated in different cohorts. Patients were allocated to the MMC cohort before the 90 Y procedure. The first cohort (A) received one cycle of 6mg MMC, the second cohort (B) received one cycle of 12mg MMC, the third cohort (C) received 2 cycles of 12mg of MMC and the fourth cohort (D) received the standard regime of MMC infusion consisting of a maximum of 6 cycles of each 12mg of MMC. Before and after the MMC infusion laboratory results were taken to determine whether the dose could be tolerated. The dose of MMC was adjusted when thrombocyte count was < 100x10 9 thrombocytes/L. In the last cohort, the effect of MMC was radiologically evaluated, by CT or MRI, after every two cycles. If these evaluations showed no further intra-or extra-hepatic disease progression, the patient was rescheduled for the next 2 cycles for a maximum of 6 cycles.
Outcomes
The primary outcomes of this study included the feasibility and safety of MMC infusion after 90 Y SIRT. The feasibility was defined as the number of patients receiving the MMC infusion after 90 Y treatment. The safety was determined by the number of grade 3 and higher adverse events after MMC and 90 Y treatment and documented by the Common Terminology Criteria for Adverse Events version 5.0. For the response assessment the modified response evaluation criteria in solid tumours (mRE-CIST) was used to measure hepatic response by a maximum of two target lesions and categorized into four categories [Complete Response (CR), Partial Response (PR), Stable Disease (SD) and Progressive Disease (PD)]. 15 
Statistical analysis
Patient and pre-treatment characteristics were presented as numbers, percentages and median time Table 2 shows the patient characteristics of the 16 treated women. The median time from diagnosis of metastatic breast cancer to start of the study was 28 months (range 7.7-91.0 months). Patients were 26-77 (median 59) years old at the start of the study.
Results

Patient characteristics
A liver biopsy was taken before start of the study in 15 patients and showed a positive oestrogen receptor in 8 patients, positive progesterone receptor in 8 patients and a negative HER2-neu status in all patients (n = 15). Six patients had a triple negative receptor status. Tumour burden of the liver was < 25% in 9 patients and > 25% in 7 patients. Nine patients had extra-hepatic disease with a median of 1 site (range 0-4) and bone (n = 5) as most common site. Before inclusion, the median number of chemotherapy lines in the metastatic phase was 3 regimes consisting of anthracyclines in 75% and taxanes in 81%. Figure 1 shows a treatment overview of the 16 patients. All 16 patients underwent the 90 Y procedure whereby pre-embolization of extra hepatic arteries was performed in 14/16 patients. A median dose of 1.68 GBq (range 1.043-2.140) was inserted in both liver lobes (n = 14) or one liver lobe (n = 2). At response evaluation five patients showed extra-hepatic disease progression, of whom, three patients were excluded for additional MMC infusion and two patients received the sequential MMC infusion, but with additional therapy of Exemestane (Aromasin®) for stabilization of their extra-hepatic disease. One patient was hospitalized after 90 Y SIRT for 2.5 weeks because of the side effects of the 90 Y treatment and excluded from further treatment. Median time between 90 Y SIRT and first MMC infusion was 2.1 months (range 1.7-12.8 months). In one patient an interval of 12.8 months occurred, because of PD in the liver after 90 Y treatment. This patient first received systemic chemotherapy and after progression during this systemic chemotherapy the MMC infusion was administrated. A total of 12 patients were treated in four different cohorts of MMC doses after the 90 Y treatment (Figure 1) . In cohort D, the maximum of 6 cycles of 12 mg MMC was administrated in 2 patients. In the other four patients the dose was adjusted (n = 2) and discontinued (n = 2) due to hematologic toxicity (thrombocytopenia) and disease progression. Table 3 shows the adverse events after the 90 Y SIRT and MMC infusion. After the 90 Y treatment one grade 3 adverse event occurred, consisted of a gastric ulcer treated with proton pump inhibitors and hospitalization. The most common grade 1/2 adverse events after 90 Y SIRT were pain 7/16, nausea 
Treatment
Adverse events
Response, follow up and survival
Response evaluation of the liver after 6 to 8 weeks after 90 Y treatment (n = 16) revealed PR in 10 patients and SD in 6 patients ( Figure 2 ). Extra hepatic response evaluation showed PD in 5 patients and SD in 11 patients. Additional hepatic response of MMC infusion after 90 Y treatment was PR in 4/12 patient, SD in 5/12 patients and PD in 3/12 patients.
After the study, nine patients were eligible to receive systemic chemotherapy and one patient was eligible for surgery and underwent a segmentectomy. The median OS was 12.6 months (95% CI 10.23-15.0).
Discussion
Intra-arterial therapy is a treatment option in patients with chemo-refractory liver dominant metastatic breast cancer. 6 In our institute MMC infusions are performed for almost 20 years for chemo refractory LMBC whereby a disease control of 58% is obtained with low grade adverse events. 9 In the present study we investigated whether MMC infusion is feasible and safe after 90 Y SIRT.
The sequential treatment of 90 Y followed by MMC was possible in 75% (12/16) of the enrolled patients. Only low-grade adverse events (grade 1 and 2) were observed after the MMC infusions. In addition, the gradual escalation of the MMC infusions, ranging from 6 mg in 1 cycle to a maximum of 72 mg in 6 cycles, caused no additional adverse events.
During the regular MMC protocol of our institute, patients can receive a maximum of 72 mg in 6 cycles whereby close monitoring is performed to adjust, postpone or stop the MMC infusion after each cycle. 9 In current study, the same protocol was followed in the last cohort, subsequently 4 patients did not receive all 6 MMC cycles. Thus, this pilot shows that the regular protocol of MMC can be followed after prior treatment with 90 Y. Patients maintained their performance status after the sequential treatments, and so 9/12 patients were eligible for systemic therapy afterwards and 1/12 even for hepatic surgery. Therefore, this combination treatment can be used as a drug holiday from systemic treatment.
We did observe a high number of gastrointestinal ulcers after 90 Y SIRT (n = 5, 31%). All these patients underwent pre-embolization and received a bilobar treatment in the left and right hepatic artery. Despite these precautions, the ulcers occurred probably due to reflux and non-target deposition of the 90 Y resin microspheres which is a known risk of 90 Y treatment for LMBC. 16 After the introduction of an anti-reflux catheter in the last 6 patients, no more ulcers occurred. According to the literature, several factors are associated with reflux of 90 Y resulting in gastrointestinal ulcering, namely prior administration of monoclonal antibodies (i.e. bevacuzimab, trastuzumab), the type of 90 Y microspheres and the dose of 90 Y. 10, 17 In the present study no correlations were found for prior monoclonal antibodies treatment and the dose of 90 Y with the development of gastrointestinal ulcers. The development of the gastrointestinal ulcers in the current study was probably caused by several pretreatment and treatment related factors. The use of the anti-reflux catheter showed improvement with no further reported gastrointestinal ulceration. Therefore, caution is needed in future studies.
The median OS of radioembolization in LMBC patients ranges from 6.6-13.6 months, which is in line with the median OS of 12.6 in this study. 10, 11, [18] [19] [20] The median OS was higher compared to earlier studies where patients received only MMC infusion (12.6 versus 7.6 months). 9, 14 However, the inclusion criteria for this study were more strict than our routine indications for MMC infusion. Consequently, patients had less extensive local and extra hepatic disease with a better performance status compared to our previous reported cohort of patients treated with MMC infusion only.
The main limitation of this study consists of small patient number in the cohorts and the long inclusion period.
Conclusions
In conclusion, the sequential treatment of intra-arterial infusion of MMC after 90 Y therapy is feasible with limited low-grade adverse events after MMC. The regular MMC protocol can be followed with adjustment of MMC dose based on clinical, radiological and biochemical parameters. However, caution is needed to prevent reflux after 90 Y SIRT in LMBC patients. Further research is needed to show whether the combination of 90 Y and MMC has a benefit over the treatment of MMC or 90 Y alone in LMBC patients.
